Journal of Clinical Oncology
Journal · Lippincott Williams & Wilkins · ISSN 0732-183X
174,175 papers · 4,495,992 citations · h-index 741 · impact 1.7
Journal websiteOpenAlexLung Cancer Treatments and MutationsCancer Treatment and PharmacologyCancer Genomics and DiagnosticsColorectal Cancer Treatments and StudiesCancer Immunotherapy and BiomarkersProstate Cancer Treatment and Research
Latest papers
- Perioperative Durvalumab for Resectable Non–Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN TrialJohn V. Heymach, Jie He, David Harpole et al. · Journal of Clinical Oncology · 2026
- Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER TrialYu Sunakawa, Manabu Shiozawa, Takanori Watanabe et al. · Journal of Clinical Oncology · 2026
- Prior BRAF Inhibitor Exposure Is Not Enough to Define Resistance in the Phase I Mosperafenib StudyChangjiang Zhao, Luo Ruiyu, He Yan et al. · Journal of Clinical Oncology · 2026
- Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration TherapyOthman Al‐Sawaf, Can Zhang, Mohammad S. Esfahani et al. · Journal of Clinical Oncology · 2026
- Speeding to a Stop: Postapproval Barriers to Accessing New Lung Cancer TherapiesIbiayi Dagogo‐Jack · Journal of Clinical Oncology · 2026
- Targeting ErbB-Family Receptors in Small Cell Lung Cancer: Clinical Activity and an Unresolved MechanismJunko Tanizaki · Journal of Clinical Oncology · 2026
- Reply to: Prior BRAF Inhibitor Exposure Is Not Enough to Define Resistance in the Phase I Mosperafenib StudyMaría Vieito, Elisa Fontana, Gabriel Schnetzler et al. · Journal of Clinical Oncology · 2026
- Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0Jennifer L. Caswell‐Jin, Mark R. Somerfield, Muhammad Ali Khan et al. · Journal of Clinical Oncology · 2026
Most cited
- The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.David Cella, David S. Tulsky, Geoffrey V. Gray et al. · Journal of Clinical Oncology · 19936,073cited
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 19975,914cited
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationBruce D. Cheson, Richard I. Fisher, Sally F. Barrington et al. · Journal of Clinical Oncology · 20145,685cited
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic SubtypesJoel S. Parker, Michael E. Mullins, Maggie C.U. Cheang et al. · Journal of Clinical Oncology · 20094,947cited
- Final Version of 2009 AJCC Melanoma Staging and ClassificationCharles M. Balch, Jeffrey E. Gershenwald, Seng-Jaw Soong et al. · Journal of Clinical Oncology · 20094,601cited
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJames C. Yao, Manal M. Hassan, Alexandria T. Phan et al. · Journal of Clinical Oncology · 20084,553cited
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerAntonio C. Wolff, M. Elizabeth H. Hammond, Jared N. Schwartz et al. · Journal of Clinical Oncology · 20064,485cited
- Revised Response Criteria for Malignant LymphomaBruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 20074,466cited
Profile assembled from OpenAlex, the open catalog of scholarly work. Metrics reflect OpenAlex’s coverage and may differ from other databases; “impact” is OpenAlex’s two-year mean citedness, comparable to a journal impact factor.
Your own research deserves this workspace
Search and screen literature, follow authors and journals, analyze your data, and write in your own voice — in one place.